The number of cancer survivors continues to increase in the United States due to the growth
and aging of the population as well as advances in early detection and treatment. To assist …

BACKGROUND The 5‐year relative survival for prostate cancers diagnosed between 1990
and 1994 in the United States was very high (92%); however, survival in black males was …

Prostate cancer (PCa) is the most commonly diagnosed malignancy in males, and, in the
United States, is the second leading cause of cancer-related death for men older than 40 …

Abstract Steroidogenic factor 1 (sf1)(officially designated as nuclear receptor subfamily 5
group A member 1 [NR5A1]) is an important regulator of gonad development. Previous …

Objective To determine whether African Americans (AAs) with intermediate-to high-risk
prostate cancer (PCa) receive similar treatment as white patients and whether any observed …

Objectives To examine the effects of racial residential segregation and structural racism on
the diagnosis, treatment, and outcomes of patients with prostate cancer. Patients and …

Prostate cancer (PCa) is frequently diagnosed in men, and dysregulation of microRNAs is
characteristic of many cancers. MicroRNA-1207-3p is encoded at the non-protein coding …

Background In 2012, the United States Preventive Services Task Force (USPSTF)
recommended against prostate-specific antigen (PSA) screening, despite evidence that …

Background: The Affordable Care Act (ACA) aims to expand health insurance coverage to
over 30 million previously uninsured Americans. To help evaluate the potential impact of the …

Background: Racial disparities in prostate cancer incidence and mortality rates are
considerable. We previously found in the Health Professionals Follow-up Study (HPFS) that …